SOURCE: Research and Markets

Research and Markets

April 04, 2016 08:55 ET

Global Cancer Vaccine Market & Clinical Trial Insight

Increases Due to Less Side Effects, Low Toxicity & High Specificity

DUBLIN, IRELAND--(Marketwired - April 04, 2016) -  Research and Markets has announced the addition of the "Global Cancer Vaccine Market & Clinical Trial Insight" report to their offering.

The cancer vaccines have revolutionized the present views and methodologies of cancer treatment. As a result of which plenty of biotech companies are exploring the field of cancer vaccines. This has caused the development of numerous cancer vaccines for numerous types of cancer.

Pharmaceutical companies are using these vaccines for clinical trials; few of them are already available to the patients across the world. The US and EU were the first markets to approve the cancer vaccines for therapeutic usage. As compared to rest of the world, commercialization and development in these regions have already made a significant progress.

The attractiveness for cancer vaccines has increased in past few years due to their characteristic properties like less side effects, low toxicity and high specificity. Besides, innovations related to novel delivery methods have also made them a lucrative option. Unlike traditional methods, they can be used for targeting the sub-group of cancers without effecting normal cells. Another factor in their favor is their high efficacy levels as compared to the presently available cancer therapeutics.

The market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category.

Companies Profiled:

  • Advaxis
  • AVAX Technologies
  • Celldex Therapeutics
  • Dendreon Corporation
  • Galena Biopharma
  • GlaxoSmithKline
  • ImmunoCellular Therapeutics
  • ImmunoGen
  • Inovio Pharmaceuticals
  • KAEL-GemVax
  • Liponova
  • MedImmune
  • Merck
  • NeoStem Oncology
  • NewLink Genetics
  • Northwest Biotherapeutics
  • Novartis
  • Peregrine Pharmaceuticals
  • Recombio
  • Roche
  • Sanofi
  • Seattle Genetics
  • Valeant Pharmaceuticals

Report Highlights:

  • Global Cancer Market Overview
  • Emergence of Personalized Cancer Vaccines
  • Platforms for Cancer Vaccines Delivery
  • Mechanism of Cancer Vaccines
  • Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country
  • Global Cancer Vaccine Clinical Pipeline: 298 Vaccines
  • Marketed Cancer Vaccines: 15 Vaccines
  • Regulatory Framework for Cancer Vaccines Development & Marketing

For more information visit

Sector: Clinical Trials

Contact Information

  • Research and Markets
    Laura Wood
    Senior Manager

    For E.S.T Office Hours Call 1-917-300-0470
    For U.S./CAN Toll Free Call 1-800-526-8630
    For GMT Office Hours Call +353-1-416-8900

    U.S. Fax: 646-607-1907
    Fax (outside U.S.): +353-1-481-1716